H71.93
Unspecified cholesteatoma, bilateral
Clinical Classification Guidelines
Medical Intelligence & Overview
Unspecified bilateral cholesteatoma is a condition characterized by the abnormal growth of skin cells in the middle ear cavity on both sides of the head. This benign (non-cancerous) growth can lead to hearing issues and other ear-related problems if not properly managed. The term 'unspecified' indicates that the exact type or cause of the cholesteatoma hasn't been specifically classified. Because it affects both ears, it is termed as 'bilateral,' which can pose unique challenges in diagnosis and treatment.
Causes & Symptoms
Clinical Causes: Chronic middle ear infections leading to tissue damage and abnormal skin growth Eustachian tube dysfunction causing improper ventilation of the middle ear Previous ear surgeries or trauma that may alter ear structure Congenital factors, where the condition is present at birth Poor drainage of the middle ear, leading to accumulation of keratinizing skin cells Genetic predisposition in some individuals
Key Symptoms: Gradual hearing loss in affected ears Ear fullness or pressure sensation Recurrent or persistent ear infections Discharge from the ear that may be foul-smelling Possible dizziness or balance disturbances in advanced cases Occasional pain or discomfort around the ear
Diagnostic & Treatment
Diagnosis Path: Diagnosis of bilateral cholesteatoma involves several steps including:
Treatment Protocols: Treatment options for bilateral cholesteatoma typically include surgical intervention to remove the growth and repair any damage to the middle ear structures. The goal is to eradicate the cholesteatoma, restore hearing, and prevent complications. Surgery may involve:
Clinical Advice & FAQs
Billing Guidance
Is H71.93 a billable ICD-10 code?
Yes, H71.93 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report H71.93?
Clinical documentation must specify the nature of Unspecified cholesteatoma, bilateral and any associated comorbidities for accurate reporting.
Cite this Clinical Reference